• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Instil Bio Inc.

    2/13/25 4:14:32 PM ET
    $TIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TIL alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Instil Bio, Inc.

    (Name of Issuer)


    Common Stock, $0.000001 par value per share

    (Title of Class of Securities)


    45783C101

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    45783C101


    1Names of Reporting Persons

    BML Investment Partners, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    400,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    400,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    400,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.1 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    45783C101


    1Names of Reporting Persons

    Leonard Braden Michael
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    40,000.00
    6Shared Voting Power

    400,000.00
    7Sole Dispositive Power

    40,000.00
    8Shared Dispositive Power

    400,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    440,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.7 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Instil Bio, Inc.
    (b)Address of issuer's principal executive offices:

    3963 Maple Avenue, Suite 350, Dallas, Texas, 75219
    Item 2. 
    (a)Name of person filing:

    BML Investmetn Partners, L.P>
    (b)Address or principal business office or, if none, residence:

    65 E Cedar - Suite 2
    (c)Citizenship:

    Delaware
    (d)Title of class of securities:

    Common Stock, $0.000001 par value per share
    (e)CUSIP No.:

    45783C101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    440000
    (b)Percent of class:

    6.74  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    40000

     (ii) Shared power to vote or to direct the vote:

    400000

     (iii) Sole power to dispose or to direct the disposition of:

    40000

     (iv) Shared power to dispose or to direct the disposition of:

    440000

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    BML Investment Partners, L.P.
     
    Signature:Braden M Leonard
    Name/Title:BML Capital Management, LLC its General Partner By: Braden M Leonard, its Managing Member
    Date:02/13/2025
     
    Leonard Braden Michael
     
    Signature:Braden M Leonard
    Name/Title:Leonard Braden Michael
    Date:02/13/2025
    Get the next $TIL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TIL

    DatePrice TargetRatingAnalyst
    1/7/2025$11.00 → $52.00Hold → Buy
    Jefferies
    1/7/2025$11.00 → $52.00Hold → Buy
    Truist
    11/4/2024Mkt Perform
    JMP Securities
    4/12/2024$5.00 → $11.00Buy → Hold
    Jefferies
    11/1/2022$16.00 → $6.00Buy → Hold
    Truist
    11/1/2022Outperform → Market Perform
    Cowen
    8/13/2021$34.00Outperform
    Robert W. Baird
    8/13/2021$34.00Outperform
    Baird
    More analyst ratings

    $TIL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Instil Bio Inc.

      SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)

      11/14/24 6:59:16 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Instil Bio Inc.

      SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)

      11/14/24 5:48:56 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Instil Bio Inc.

      SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)

      10/25/24 9:42:03 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TIL
    Leadership Updates

    Live Leadership Updates

    See more
    • Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update

      Manufacturing update on voluntary pause of DELTA-1 trial of ITIL-168 in advanced melanoma expected in Q1'23 Reprioritization of resources with enrollment deferred in DELTA-2 trial of ITIL-168 First patient with non-small cell lung cancer dosed with ITIL-306, the first engineered TIL therapy using CoStAR Platform, with plans to share clinical data in 2023 Appointment of cell therapy pioneer Dr. Robert Hawkins as Head of Research and Development, and resignation of Chief Medical Officer, Dr. Zachary Roberts Company confirms cash runway into 2025 with anticipated sale-leaseback transaction of its Tarzana manufacturing facility DALLAS, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("

      11/14/22 4:07:40 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Instil Bio Announces Appointment of Tim Moore as Chief Operating Officer

      DALLAS, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced the appointment of Tim Moore to the role of Chief Operating Officer. Tim Moore has more than three decades of leadership experience in biopharmaceutical manufacturing and operations, including at Genentech, Kite and most recently PACT Pharma. From 2016 to 2019, Mr. Moore was Executive Vice President, Technical Operations at Kite Pharma, where he was responsible for technical operations and successfully launched Yescarta®, one of the fi

      9/6/22 7:00:00 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TIL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CFO and CBO Laumas Sandeep

      4 - Instil Bio, Inc. (0001789769) (Issuer)

      4/28/25 5:00:42 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CEO and Chairman Crouch Bronson

      4 - Instil Bio, Inc. (0001789769) (Issuer)

      4/28/25 5:00:15 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CFO and CBO Laumas Sandeep

      4 - Instil Bio, Inc. (0001789769) (Issuer)

      9/23/24 1:12:01 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TIL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $TIL
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $TIL
    SEC Filings

    See more
    • Instil Bio upgraded by Jefferies with a new price target

      Jefferies upgraded Instil Bio from Hold to Buy and set a new price target of $52.00 from $11.00 previously

      1/7/25 8:29:55 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Instil Bio upgraded by Truist with a new price target

      Truist upgraded Instil Bio from Hold to Buy and set a new price target of $52.00 from $11.00 previously

      1/7/25 8:29:34 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JMP Securities initiated coverage on Instil Bio

      JMP Securities initiated coverage of Instil Bio with a rating of Mkt Perform

      11/4/24 7:41:54 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      Clinical data for AXN-2510/IMM2510 monotherapy in relapsed/refractory NSCLC in China by ImmuneOnco, as well as additional safety data in other solid tumors, anticipated in 1H 2025 Enrollment of 1L NSCLC patients in trial of AXN-2510/IMM2510 and chemotherapy by ImmuneOnco in China anticipated to begin in Q2 2025 with initial clinical data by ImmuneOnco expected in 2H 2025 Initiation of U.S. clinical study of AXN-2510/IMM2510 in combination with chemotherapy in 1L NSCLC anticipated before the end of 2025, assuming receipt of necessary regulatory approvals DALLAS, March 04, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("I

      3/4/25 7:09:26 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody

      ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China ImmuneOnco announced initial clinical data from the 1L advanced NSCLC trial in China is expected as early as 2H 2025 Instil is targeting initiation of a potential first-line advanced NSCLC clinical trial of IMM2510/SYN-2510 combined with chemotherapy in 2H 2025, assuming necessary regulatory approvals DALLAS, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (NASDAQ:TIL, "Instil")), today announced clinical progress of IMM2510/SYN-2510 in China by its collaborator, ImmuneOnco Biopharmaceutica

      1/14/25 7:00:37 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

      Licensed SYN-2510, a potential best-in-class PD-L1xVEGF bispecific antibody, for global ex-China development and commercialization Clinical data update for SYN-2510/IMM2510 in China from ImmuneOnco anticipated in 1H 2025 Initiation of Phase 1b/2 SYN-2510/IMM2510 + chemotherapy combination in first-line non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC) anticipated in late 2024 and 1H 2025, respectively, by ImmuneOnco in China U.S. clinical study of SYN-2510/IMM2510 in NSCLC initiation targeted for 2H 2025 DALLAS, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a

      11/13/24 7:00:00 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFR14A filed by Instil Bio Inc.

      DEFR14A - Instil Bio, Inc. (0001789769) (Filer)

      5/2/25 5:00:20 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Instil Bio Inc.

      DEFA14A - Instil Bio, Inc. (0001789769) (Filer)

      4/14/25 4:30:40 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Instil Bio Inc.

      DEF 14A - Instil Bio, Inc. (0001789769) (Filer)

      4/14/25 4:30:08 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care